Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
BT-549 | Alpelisib | PI3Ka | PI3K/mTOR | 17.5141 | 0.6841 | 0.0322 | 0.0099 | 1.0429 | 49.8384 | 0.95639 |
BT-549 | Ipatasertib | AKT | PI3K/mTOR | 12.6362 | 0.4956 | 0.1735 | 0.0097 | 0.5079 | 1.6786 | 0.97652 |
BT-549 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 2.2065 | 0.0950 | 0.2229 | 0.0263 | 0.5717 | 15.0749 | 0.99278 |
BT-549 | Olaparib | PARP | Misc | 11.948 | 0.5432 | 0.0657 | 0.0130 | 0.9548 | 37.7564 | 0.91931 |
BT-549 | A-1210477 | Mcl-1 | Misc | Inf | 0.9540 | 0.0083 | 0.0018 | 0.0000 | Inf | 0.34182 |
BT-549 | Volasertib | PLK | Cell cycle | 0.0088352 | -0.2289 | 0.5676 | 0.1490 | 2.4967 | 0.0098732 | 0.99586 |
BT-549 | Bleomycin | Radiation | Misc | 0.17998 | -0.0141 | 0.4667 | 0.1506 | 1.0031 | 0.20287 | 0.99525 |
BT-549 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.8097 | 0.0568 | 0.0017 | 0.6702 | 0.72927 | 0.89208 |
BT-549 | Saracatinib | SRC | MAPK/nRTK | Inf | 0.5558 | 0.0348 | 0.0015 | 3.3790 | 3.6758 | 0.97565 |
BT-549 | AZD7762 | CHK1/2 | Cell cycle | 0.066029 | -0.4824 | 0.6356 | 0.2312 | 1.6999 | 0.087287 | 0.97383 |
BT-549 | Palbociclib | CDK4/6 | Cell cycle | Inf | 1.0500 | -0.0401 | -0.0011 | 0.0000 | Inf | -9.2879 |
BT-549 | Abemaciclib | CDK4/6 | Cell cycle | 3.9707 | 0.0333 | 0.1267 | 0.0188 | 1.2825 | 7.5655 | 0.99654 |
BT-549 | ABT-737 | Bcl2/XL | Misc | Inf | 0.9359 | -0.0225 | 0.0062 | 0.0000 | Inf | 0.067883 |
BT-549 | Taxol | Chemo | Chemotherapy | 0.0027257 | -0.2074 | 0.6989 | 0.2304 | 1.9420 | 0.0030953 | 0.98743 |
BT-549 | Doxorubicin | Chemo | Chemotherapy | 0.006482 | -0.3312 | 0.7603 | 0.1972 | 1.5744 | 0.0079126 | 0.9824 |
BT-549 | Topotecan | Topo I | Chemotherapy | 0.0084727 | -0.2410 | 0.8509 | 0.2269 | 1.4734 | 0.010061 | 0.9801 |
BT-549 | Cisplatin | Chemo | Chemotherapy | 1.016 | 0.0674 | 0.2835 | 0.0552 | 1.0827 | 1.0937 | 0.98489 |
BT-549 | Etoposide | Topo II | Chemotherapy | 0.181 | -0.1948 | 0.4726 | 0.1408 | 1.1701 | 0.22766 | 0.99526 |
CAL-120 | Abemaciclib | CDK4/6 | Cell cycle | 0.247 | -0.1408 | 0.4780 | 0.0849 | 0.3730 | 4.696 | 0.95026 |
CAL-120 | Palbociclib | CDK4/6 | Cell cycle | Inf | 0.6687 | 0.1422 | 0.0012 | 1.4451 | 0.023318 | 0.96675 |
CAL-120 | AZD7762 | CHK1/2 | Cell cycle | 0.15216 | -0.4949 | 0.5265 | 0.2150 | 1.1035 | 0.26511 | 0.97495 |
CAL-120 | Volasertib | PLK | Cell cycle | 0.0018536 | 0.0258 | 0.6758 | 0.2649 | 2.5191 | 0.001844 | 0.99276 |
CAL-120 | Dinaciclib | pan CDK | Cell cycle | 0.009892 | -0.1320 | 0.5549 | 0.1203 | 4.4157 | 0.010404 | 0.99947 |
CAL-120 | Doxorubicin | Chemo | Chemotherapy | 0.009438 | -0.2475 | 0.6969 | 0.1356 | 1.3775 | 0.011488 | 0.99278 |
CAL-120 | Cisplatin | Chemo | Chemotherapy | 2.9328 | 0.1876 | 0.1824 | 0.0229 | 0.9231 | 4.0426 | 0.98856 |